In the past year, with the efforts of the National Health Insurance Bureau, as many as 17 anticancer drugs were officially included in the medical insurance. Recently, the national health insurance bureau announced once again that a new round of medical insurance drug catalog adjustment is coming. In the future, anticancer drugs and drugs for major diseases will be included in the medical insurance. The following will take you to understand the medical insurance prices of 17 anticancer drugs in 2019.
A new round of medical insurance drug catalog adjustment
On March 13, the national medical insurance bureau announced the "2019 national medical insurance drug catalog adjustment work plan (Draft)" to solicit public opinions. The public can put forward their opinions before March 26, 2019. According to the arrangement, the new version of the routine access medical insurance drug catalog will be published in June, and all the drugs in the catalog will be adjusted in September.
The adjustment of the drug list will involve three parts: Western medicine, Chinese patent medicine and Chinese herbal pieces, including two items: drug transfer in and drug transfer out. Based on the drug information approved for listing by the State Food and drug administration, it does not accept the application or recommendation of enterprises, and does not charge assessment fees and other fees.
The imported western medicine and Chinese patent medicine shall be registered and listed by the State Drug Administration before December 31, 2018. Priority should be given to national essential drugs, drugs for treatment of major diseases such as cancer and rare diseases, drugs for chronic diseases, drugs for children, and drugs for emergency rescue.
If the original drugs in the drug catalogue have been prohibited from production, sale and use by the state drug regulatory department, they shall be transferred out; if there are other drugs that do not meet the requirements and conditions of medical insurance, they can be transferred out after the corresponding evaluation procedures.
Meanwhile, we should adjust and improve the general rules and management methods of drug catalogue, standardize the name and dosage form of drugs, and appropriately adjust the category of drugs a and B and the classification structure of drug catalogue. In the process of category adjustment, priority should be given to essential drugs.
The public can put forward their opinions by email and letter before March 26, 2019.
List of medical insurance prices of 17 anticancer drugs in 2019
These 17 kinds of negotiation anti-cancer drugs involve non-small cell lung cancer, kidney cancer, colorectal cancer, melanoma, lymphoma and other cancer species, of which 10 drugs are listed after 2017.
Fifteen expensive anticancer drugs, including gefitinib, Herceptin, Vanke, and rituximab, have reduced their prices through negotiation, with an average decrease of nearly half. The original price of Herceptin was 24500 yuan, and the price was reduced to 7600 yuan.
Wanke (bortezomib) is 13600 yuan / piece before price reduction and 6116 yuan / piece after price reduction. The original price of rituximab was 16041 yuan / bottle, but after the price reduction, it was 8298 yuan / bottle. The original price of avermectin (bevacizumab) was 5398 yuan / bottle, and it was 1998 yuan / bottle after price reduction. Iressa (gefitinib) dropped from 15000 yuan / box to 2358 yuan / box.
In general, according to the data released by the National Health Insurance Bureau, the 17 anticancer drugs cover a wide range of diseases, and their prices have dropped by more than 50% compared with the original. People who are concerned about the adjustment of the medical insurance drug catalog can submit their opinions to the National Health Insurance Bureau by email before March 26.